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Background: Generalized atrophic benign epidermoly­
sis bullosa (GABEB) is a form, of nonlethal junctional epi­
dermolysis bullosa, clinically characterized by general­
ized blistering after birth, atrophic healing, and incomplete 
universal atrophic alopecia with onset in childhood. Re­
cently, we discovered a deficiency of the 1.80-kd bullous 
pemphigoid antigen (BP180) and a reduced amount of 
BP180 messenger RNA in three patients with GABEB. It 
is not yet clear, however, whether GABEB is invariably 
caused by BP 180 deficiency.
Results: We examined 18 patients with nonlethal junc­
tional epidermolysis bullosa from unrelated families; nine 
of these individuals presented with the clinical character­
istics of GABEB. Specimens of clinically normal skin ob­
tained from the patients were stained by immunofluores­
cence with monoclonal antibodies to BP 180 and laminin-5. 
The BP180 epitopes were not expressed in eight patients,
all of whom were sharing the typical clinical features of 
GABEB. In one of the nine patients with GABEB, the BP180 
level was sufficient, but the laminin-5 level was reduced. 
Among the nine patients 
losa without atrophic alopecia, laminin-5 level was not 
expressed in one patient, while in the other patients both 
antigens were normally expressed.
Conclusions: Not all patients with GABEB are defi­
cient in BP 180, since some individuals with GABEB only 
exhibit reduction of the laminin-5 expression. The BP 180 
deficiency in the skin invariably seems to result in GABEB. 
Immunofluorescence analysis using monoclonal anti­
bodies against BP 180 (and laminin-5) may allow early 
subtyping, which is of prognostic significance, in chil­
dren born with junctional epidermolysis bullosa.
(Arch Dermatol 1996;132:145-150)
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en era lized  atrophic be- Normal growth and lack of anemia are 
nign epidermolysis bul- typical, as is moderate improvement with 
losa (GABEB) is a clini- advancing age. In a consensus elassifica- 
cal variant of junctional tion made in 1991,4 GABEB was grouped 
epidermolysis bullosa together with other nonlethal general-
(JEB). The term GABEB was coined in 
1982 by Iiintner and Wolff1 and is syn­
onym ous with epidermolysis bullosa 
atrophicans generalisata mitis.2 The Erst 
kindred with GABEB was 
1976 by Hashimoto et aP *
2, according to the or
ABEB
healing with
of re-
ized JEB forms into the category general­
ized nonlethal JEB, differing from, Herlitz 
disease (generalized lethal JEB) by its ab­
sence of anemia and growth retardation.4 
H ow ever, the  ty p ic a l  a lo p e c ia  in  
GABEB distinguishes it from other forms 
of nonlethal JEB.
Recently, Jonkm an et al3
strated that 180-kd bullous pemphigoid
is a C£
GABEB.5,6 In three patients with
ar epi-no scarring or milia. the intracellular and
Characteristic is a follicular atrophy (not topes of the BP 1.80 molecule were
cicatricial) beginning in childhood and re- in clinically normal skin. Northern blot
suiting in scalp baldness (particularly analysis of cultured keratinocytes ob- 
above the ears), partial absence of eye­
lashes and eyebrows, and the absence of 
body, pubic, and axillary hair (universal
as tic or
trophic, the dentition is affected, and the
mucous
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PATIENTS AND METHODS
PATIENTS
Eighteen patients with nonlethal JEB were included 
in the study: 13 patients with a generalized type and 
five patients with a localized or inverse type. The clini­
cal features are summarized in T able I . Patients 1 
through 35, 4 ,10 6,11(p 155) 8 ,12 and 1313 have been de­
scribed previously. The diagnosis of nonlethal JEB was 
established in each patient on the basis of clinical find­
ings, family history, antigen mapping, and electron mi­
croscopy. Ultrastructurally, all patients had hypoplas­
tic hemidesmosomes in clinically normal skin.
METHODS
Skin Specimens
Four-millimeter punch biopsy specimens were obtained 
from clinically normal skin (from the flexor aspect of 
the upper arm or the thigh) of the patients. Skin speci­
mens obtained from healthy adults served as controls. 
The skin specimens were snap frozen for immunofluo­
rescence.
Antibodies
Monoclonal IgGl antibodies 1D1 and lA8c are directed 
against the extracellular and intracellular domain of 
BP180, respectively, and the monoclonal IgGl antibody 
R815 is directed against the 230-kdbullous pemphigoid 
antigen (BP230).14,15 The specificity of antibodies was 
established by immunoblot on extracts of normal hu­
man keratinocy tes and of the human carcinoma cell line 
A431.5,14'15Mouse monoclonalIgG 1 antibody GB316 was 
directed against laminin-5 (nicein/kalinin/epiligrin).
Immunofluorescence Studies
Cryostat sections (4 jxm) of skin specimens were pro­
cessed for im m unofluorescence as previously de­
scribed.17 In combination with the primary mouse 
monoclonal antibodies, we used biotinylated goat anti­
mouse IgGl dilution 1:100 (SBA, Birmingham, Ala) and 
dichlorotriazmyl-amino-fluorescein-conjugatedstrep- 
tavidin, dilution 1:200 (Jackson Immuno Research Inc, 
West Grove, Pa). The nuclei were counterstained in blue 
with fluorescent bis-benzimide, dilution 1:15 000 (Serva 
GmbH, Heidelberg, Germany). Digitized video micro­
scopic images of tissue sections were obtained with a 
newly developed imaging system with long exposure 
times designed for the detection of very low levels of 
fluorescence.lH
tained from a patient with GABEB revealed a reduced level 
of BP180 messenger RNA, suggesting that the BP180 de­
ficiency was the primary defect.5 In contrast, McGrath 
et al7 found two mutations in the gene LAMC2 coding 
for the y 2  su b u n it  of lam inin-5 (n ice in /ka lin in / 
epiligrin) in three related patients with GABEB. These 
studies suggest that the deficiency of at least two candi-
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* Immunofluorescence results summarize negative or severely reduced 
staining In clinically normal skin. GABEB indicates generalized atrophic 
benign epidermolysis bullosa; BP180, 180-kd bullous pemphigoid (BP) 
antigen; BP230, 230-kd BP antigen; and moAb, monoclonal antibody.
date proteins, BP180 and laminin-5, may be responsible 
for the clinical GABEB phenotype.
See also pages 151 and 220
The BP180 is a putative cell-matrix adhesion mol­
ecule that is restricted to the hemidesmosomes of strati­
fied squamous epithelia. The sequence of the BP 180 
complementary DNA clones also shows that it is an un­
usual type II transmembrane molecule with the amino 
terminal head located intracellularly.8 Moreover, the ex­
tracellular tail of BP180 contains an interrupted collag­
enous domain, and, because of that, it was classified as 
type XVII collagen.9 However, the intracellular and ex­
tracellular ligands of BP 180, as well as the molecular and 
supramolecular structures, remain unknown at present.
In this study, we investigated the relationship be­
tween the clinical phenotype of GABEB and the molecu­
lar expression of BP180 and laminin-5. We examined 18 
patients from unrelated families with nonlethal JEB, of 
whom nine had GABEB with characteristic alopecia. Speci­
mens obtained from the clinically normal skin of the pa­
tients were examined by means of immunofluorescence 
using monoclonal antibodies to different domains of 
BP180 and laminin-5. We found that most patients with 
GABEB have BP 180 deficiency, although in a minority 
of the patients with clinically indistinguishable cases, the 
expression of laminin-5 may be reduced while BP 180 is 
normally expressed.
Nine of the 18 patients (patients 1 through 9) had the 
clinical characteristics of GABEB, with alopecia of the 
scalp, eyebrows, and eyelashes (Figure 1 ); healing with 
skin atrophy and hyperpigmentation and depigmenta­
tion (Figure 2 , top); and the absence of secondary and 
lanugo hairs (Figure 2, bottom).
Clinical features and immunofluorescence results are 
summarized in Table 1. The BP 180 antigen was not ex­
pressed in eight of the nine patients with GABEB. In all 
eight patients, both the intracellular and the extracellu-
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Figure 1. Patient 3 with BP180-negative generalized atrophic benign 
epidermolysis bullosa at the ages o f 3 years (top) and 26 years (bottom). 
Note alopecia of the scalp and eyebrows (the left eyebrow has been 
accentuated by pencil) that has developed after infancy.
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Figure 5. Patient 3 with generalized atrophie benign epidermolysis bullosa. 
Areas of skin that never blister (outlined with a black marker) show normal 
pigmentation and no atrophy in a leaflike (phylloid) pattern.
Figure 3. Immunofluorescence of control skin specimens (A and D) and of 
clinically normal skin specimens of two patients with generalized atrophic 
benign epidermolysis bullosa: patient 1 (B and E) and patient 9 (G and F) 
using antibodies 1D1 (A through C) to BP180 and GB3 (D through F) to 
laminin-5. The BP180 antigen is not expressed in patient 1 (B), while 
patient 9 has severely reduced laminin-5 expression (F). The nuclei are 
counterstained in blue. The small interruptions in the BP180 fluorescent 
line In normal skin (A) are caused by BP180-negatlve melanocytes In the 
basal layer. Bar indicates 10 ju,m.
Figure 4. Patient 9 with laminin-5-reduced generalized atrophic benign 
epidermolysis bullosa. Note the alopecia from the frontal and 
supra-auricular hair line and the loss of hair from the eyebrows and 
eyelashes.
looking skin that blisters after rubbing. According to pa­
tient 8, her entire integument had been involved.
Reactions with monoclonal antibody GB3 in the skin 
specimens from the eight BP 180-negative patients with 
GABEB revealed that laminin-5 exclusively lined the blis­
ter floor. Remarkably, in the patient with GABEB and with 
reduced laminin-5 expression (patient 9), GB3 stained 
both the blister roof and the blister floor. The split level 
seems to be lower in the lamina lucicla in this patient than
Table 2, Clinical Phenotype of Generalized 
Atrophic Benign Epidermolysis Bullosa
Generalized blistering since birth 
Blister induction after trivial trauma 
Predilection for flexor aspect of palms and fingers 
Serous and hemorrhagic blisters 
Healing with 
Skin atrophy
Hyperpigmentation and hypopigmentation 
No milia 
No scarring
Universal atrophic alopecia beginning in childhood 
Scalp (particularly above the ears)
Eyebrows (partial)
Eyelashes (partial)
Body (lanugo hair)
Secondary sexual hair (pubis and axilla)
Abnormal dentition with enamel hypoplasia 
Nail dystrophy
Mild mucosal membrane involvement 
Mild calluses on feet 
No anemia or growth retardation
it does in the lamina lucida of patients with GABEB with 
BP 180 deficiency.
Among the nine patients without atrophic alope­
cia, one patient (patient 10) was laminin-5 negative, 
while in the other three patients with generalized non- 
lethal JEB and in all five patients with the localized or 
inverse types of JEB, both BP180 and laminin-5 were 
normally expressed. One of the patients with general­
ized nonlethalJEB (patient 11) was only 3 years old; at 
that age, the clinical phenotype with alopecia may not 
yet be manifest.
C O M M E N T
In this study, we show that in the skin of the majority of 
patients with GABEB, BP180 is not expressed. How­
ever, in a minority of patients (patient 9), laminin-5 is 
reduced and BP180 is normally expressed.7 The clinical 
phenotype of GABEB with reduced laminin-5 expres­
sion is indistinguishable from that of the phenotype with 
BP180 deficiency. Thus, GABEB appears to be hetero­
geneous on the molecular level. No abnormality in the 
expression of BP180 or laminin-5 was found in a recent
ARCH DERMATOL/VOL 132, FEB 1996
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study on eight patients with GABEB that was conducted 
by Pohla-Gubo et al.,l> The discrepancy between their re-
type
not use a s
BP 180 with a high signal-noise ratio to allow a
In eight of the patients with nonlethal JEB without 
GABEB, both  BP 180 and laminin-5 levels were ex­
pressed as shown by immunofluorescence. Theoreti­
cally, there might be a defect in the genes encoding for 
BP 180 or laminin-5 in these cases that does not affect the
ise epitopes. No abnormal, expression of 
BP23Q was seen in any of the patients included in 
study.
An alternative candidate molecule for involvement 
in JEB is uncein, which is an antigen located on the an­
choring filaments in the lamina lucida, recognized by the
19-DEJ-L20 Uncein was absent in 
100% of the patients with JEB and in 25% of the patients 
with recessive dystrophic epidermolysis bullosa. The sig­
nificance of the absence of 19-DEJ-l remains unclear un-
antigen is characte ar level.
î is re-
lated to the altered expression of either BP 180 antigen 
or laminin-5, as determined by immunofluorescence. The 
clinical relevance of these findings is that patients with 
GABEB with either a BP 180 or a laminin-5 defect are clini­
cally indistinguishable. The GABEB phenotype can be dis­
tinguished from that in other patients with generalized 
nonlethal JEB using the clinical characteristics that are 
summarized in Table 2 . However, the GABEB pheno­
type appears to be incomplete at birth but becomes com­
pletely penetrant at a later age, since the characteristic 
atrophic alopecia develops in later childhood. On clini­
cal grounds, G ABEB may thus be initially classified in pa-
com
e is im i inmuno
of the skin using monoclonal antibodies
and laminin-5 may allow early subtyping
5 m
sion of BP 180 are, to date, associated only with the GABEB 
phenotype, as shown in this study and in the previous 
work.'3 Abnormalities in the expression of the laminin-5
the clinical phenotypes of gener­
ai,22 as 111
or genei In this study, one of the
patients (patient 10) was classified as having the gener-
cause of the absence of alopecia.
wasIn that patient, laminin-5 was not expressed, 
probably the result of a delect in one of the laminin-5 
genes. However, this patient was only 7 years old and the 
lull clinical GABEB phenotype might not have been de­
veloped yet.
In a series
find these lesions in our patients nor were they 
other studies on patients with G A B E B . T h u s ,  the 
large nevocytic nevi may be associated with GABEB, but
not a clinical criterion for the disorder.ire
Patient 3 presented a clinical mosaic with areas of 
never-involved skin that had a leaflike pattern (Figure 
5) similar to the phylloid pattern (non-Blaschko lines),
as described by Happle51 in mosaicism in humans with 
pigment disorders. The unique (reduced) expression of 
BP180 in the phylloid areas along 50% of the epidermal 
basement membrane zone appears to be sufficient to 
prevent skin blistering. However, the same type of 
interruptions in patient 8 did not prevent generalized 
blistering. The BP 180 interruptions in patient 3 might 
reflect somatic mosaicism, where part of the cells 
escaped the generalized autosomal recessive disorder. 
This could be the result of somatic reversion caused by 
a reverse mutation or by recombination of one of the 
two different mutations originally present on the two 
separate BP180 alleles in a compound heterozygote, 
thus rendering one allele normal. If somatic reversion 
did happen in a putative primordial stem cell, then the 
BP 180-positive patches with a diameter of 50 to 150 
|xm might reflect the area in which the keratinocytes, 
supplied by divisions of one stem cell, are localized. 
Alternatively, the interruptions might be secondary to a 
primary defect of an unknown factor that locally down- 
regulates BP 180 expression or up-regulates collagenase 
activity, in that case, the puzzling genetic explanation 
for the remarkable interrupted pattern remains the
same.
The split level of laminin-5-recluced GABEB skin ap­
pears to be lower in the lamina lucida than in the BP 180- 
cleficient GABEB skin, which is in agreement with the 
ultralocalization of these molecules. The BP 180 antigen 
is a transmembrane glycoprotein predicted from the de­
duced amino-acid sequence of the cloned BP180 comple­
mentary DN A8 and demonstrated by immunoelectron mi- 
croscopy, u s ing  antibodies to in trace llu la r  and 
extracellular epitopes, 1'i,u while laminin-5 (GB3) is an 
extracellular matrix protein localized in the lower part 
of the lamina lucida.21 However, the definitive determi­
nation of split levels in these junctional disorders has to 
await characterization of molecular interactions and bind-
ing sites of the i proteins.
We conclude that the clinical phenotype of GABEB 
is heterogeneous on the molecular level, since the genes 
for BP 180 or laminin-5 may be involved.
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